Summary
Tuberous sclerosis complex (TSC) is the most common cause of West syndrome (WS). Currently available treatment options are ineffective in the majority of affected infants and/or associated with potential serious side effects. Based on the assumption that mTOR overactivation results in increased neuroexcitability in TSC, mTOR inhibitors have been studied as antiseizure therapy. As a result, everolimus recently received approval for the adjunctive treatment of patients aged ≥2 years with refractory TSC-associated focal and secondary generalized seizures.
However, efficacy and safety data for infants with TSC-associated WS are still lacking. Therefore, a prospective open-label observational study was initiated at our center, to evaluate everolimus add-on treatment in infants with TSC-associated WS, previously refractory to standard treatment. For this preliminary report, data from four male infants with TSC2 and a median observation period of 13 (range = 8-42) months after treatment initiation were analyzed. Two infants showed electroclinical remission until day 14 after everolimus treatment initiation. In one additional infant, hypsarrhythmia resolved. No relapse after initial response was documented. Developmental progress improved in three infants. Tolerability was similar to that described in older children. According to our preliminary results, everolimus appears to have the potential to treat successfully both spasms and hypsarrhythmia in infants with TSC-associated WS, contributing to better developmental progress.
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| INTRODUCTION
Epilepsy affects 75%-90% of people with tuberous sclerosis complex (TSC). More than 70% of them have their onset within the first year of life, with up to two-thirds presenting with infantile spasms (IS), the hallmark seizure type of West syndrome (WS). TSC2 mutations are associated with a significantly earlier presentation of epilepsy than TSC1 mutations, a higher likelihood of WS, and a worse prognosis regarding seizure control and neurodevelopmental outcomes. 1 
| MATERIALS AND METHODS
This still ongoing single-center study was approved by the Medical University of Vienna ethics committee in 2014 (EK 1363/2014).
| Study protocol
Consecutive infants with TSC-associated WS are screened at the study center. TSC is diagnosed clinically and via molecular genetic testing. 8 
| RESULTS
We report preliminary results of the first four infants with ≥ 6 months of follow-up after everolimus treatment initiation (four boys with TSC2, aged 6.0-12.0 months):
| Patients' characteristics
All infants had IS and hypsarrhythmia on the EEG at the time of everolimus treatment initiation ( Table 1 ). All of them showed developmental delay, with a total CSBS score between 0 and 17 points. The median duration of antiepileptic drug treatment prior to everolimus was 3.5 (range = 2-8) months. Patients 3 and 4 were also on a ketogenic diet (KD), which was started 4 weeks prior to everolimus. The daily dose of everolimus was median 2.75 (range = 2.5-5.0) mg/d, and the trough concentration was median 6.9 (range = 4.5-7.5 ng) ng/mL. The observation period after everolimus treatment initiation was median 13 (range = 8-42) months. (Table 2 ). However, in Patient 1, the EEG improved, changing from hypsarrhythmia to focal epileptic discharges. There was no seizure relapse after initial response during the entire observation period. At last observation, Patients 2 and 3 still were responders, and their EEGs showed focal epileptic discharges. Patients 1 and 4 were still not seizure-free. The EEG of Patient 1 showed focal epileptic discharges, and in Patient 4 hypsarrhythmia was still present. In responders, the duration of epilepsy prior to everolimus (treatment lag) was shorter compared to nonresponders (2 and 3 months vs 4 and 8 months, respectively). There were no further differences between responders and nonresponders, with regard to clinical characteristics, maximum daily dose, or blood trough concentrations of everolimus.
| Developmental outcome
At 6 months after everolimus initiation, the total CSBS scores of Patients 1, 2, and 3 had increased compared to baseline. Patients 1 and 2 showed age-appropriate results (Table 2 ). However, except for Patient 2, all infants still showed delay in expressive speech and symbolic composite.
| Safety
During the time of observation, treatment was tolerated well. In no case did everolimus have to be withdrawn. Grade I AEs were observed in all infants (mild hypertriglyceridemia in three; frequent viral infections in two). In Patients 1 and 2, treatment was interrupted for 2 months, due to extensive impetigo contagiosa and recurrent pharyngitis (grade IV AEs). Grade II and III AEs were not observed.
| DISCUSSION
The effect of mTOR inhibitors on TSC-related epilepsy has been documented by three prospective controlled 5-7 and a number of open studies. Good efficacy and tolerability in young children have been reported by others 1,5,11 and were also observed by us in a previous study. 7 In this study, results
were better in the age group 1-6 years, compared with the age group 7-18 years. Similar results were recently reported from a post hoc analysis of the phase 3 EXIST-3 trial.
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To our knowledge, we report the first prospective data on the potential benefit of everolimus add-on treatment in infants with TSC-associated WS. All four infants had failed first-line standard treatment with vigabatrin and subsequent ACTH; two of them also did not respond to KD. All infants already showed significant developmental delay. After the introduction of everolimus, electroclinical remission until day 14 was achieved in two of them; in one additional infant, hypsarrhythmia resolved. There was no relapse observed after initial response during the entire observation period of up to 42 months. In addition, we saw positive effects on developmental outcomes (ie, improvement of the total CSBS scores) in those three infants, in whom hypsarrhythmia had disappeared. We saw no differences between responders and nonresponders, except for a shorter duration of epilepsy prior to everolimus in responders.
Limiting factors of our preliminary results are the open study design and the very small sample size, which makes it difficult to assess the specific impact of everolimus on the apparent improvement observed in our patients. In essence, the possible influence of KD in Patient 3 remains unclear, despite everolimus being started 4 weeks after KD, as delayed responses (with spasm-free rates of 18% after 3 months and 33% after 24 months of KD treatment) were reported by Kossoff and coworkers. 12 Furthermore, KD and mTOR inhibitors may have complementary effects; McDaniel and coworkers found that KD can inhibit mTOR signaling in healthy rats and prevent late hippocampal mTOR activation in rats after kainic acid-induced status epilepticus. 13 In contrast, it is not plausible to assume that ACTH or spontaneous remission should have been 14 and spontaneous remission rates during the first 3 months after onset of IS have been reported between 1% and 5%. 15 In summary, our preliminary results-despite all limitations-suggest that everolimus is effective and safe in infants with TSC-associated WS. Support to start treatment in infants (and even in newborns) also comes from preclinical trials, indicating that early treatment of TSC animal models with mTOR inhibitors may prevent epileptogenesis (and by this the onset of clinical seizures) and may also decrease seizure severity and related complications, after seizure onset has already taken place. 16 Pretreatment with rapamycin was shown to reduce cell death, neurogenesis, mossy fiber sprouting, and seizure frequency, whereas treatment after onset of kainateinduced status epilepticus also decreased seizure frequencies and mossy fiber sprouting, although to a lesser extent, but had no effect on neurogenesis and cell death. 17 It is of interest in this context that in one of our patients (not included in this study), who received everolimus from the first month of life to treat giant cardiac rhabdomyomas, 18 no spasms occurred, despite multiple tubers and neuronal migration lines, with the largest being located in the left frontal lobe. After everolimus withdrawal at age 3 years, rapid regrowth of rhabdomyomas was observed, and focal (left frontal lobe) seizures occurred that were completely controlled when everolimus was readministered. The patient is now 6 years of age, seizure-free for 3 years, and so far shows normal development. Our results should therefore stimulate prospective controlled multicenter studies, evaluating everolimus in TSCrelated WS. Finally, TSC-associated WS could serve as model for WS due to other mTOR-mediated pathologies (eg, dysplasia type IIB).
| CONCLUSION
Our preliminary results demonstrate that everolimus can effectively stop IS and hypsarrhythmia (even after failure of first-line treatment), resulting in developmental progress. In addition, tolerability does not seem to differ from that reported in older children. The effect of everolimus might be optimized when it is started early after seizure onset or even before the onset of seizures. Prospective controlled multicenter studies are needed to corroborate our results and to define predictors for (non)response. consultancy honoraria from Novartis, Cyberonics (Livanova), UCB, and Eisai. The other authors have no conflicts of interest to report. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
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